This is the first reported case of Kaposi sarcoma in a patient receiving ruxolitinib. Ruxolitinib has immunosuppressive properties through inhibition of JAK-STAT pathway, causing functional impairment of NK cells and CD4+ lymphocytes. Monitoring for reactivation or acquisition of unusu al viral infections is mandatory during ruxolitinib treatment; the spontaneous disea se regression after therapy interruption might favor early stopping.
Kaposi Sarcoma in a patient treated with Ruxolitinib / Loscocco, G. G.; Vannucchi, M.; Paoli, C.; Franci, A.; Pieri, L.; Annunziato, F.; Massi, D.; Vannucchi, A. M. - In: ANNALS OF ONCOLOGY. - ISSN 0923-7534. - ELETTRONICO. - (2017), pp. 1-5. [10.1093/annonc/mdx188]
Kaposi Sarcoma in a patient treated with Ruxolitinib
LOSCOCCO, GIUSEPPE GAETANO;PAOLI, CHIARA;FRANCI, ANNALISA;ANNUNZIATO, FRANCESCO;MASSI, DANIELA;VANNUCCHI, ALESSANDRO MARIA
2017
Abstract
This is the first reported case of Kaposi sarcoma in a patient receiving ruxolitinib. Ruxolitinib has immunosuppressive properties through inhibition of JAK-STAT pathway, causing functional impairment of NK cells and CD4+ lymphocytes. Monitoring for reactivation or acquisition of unusu al viral infections is mandatory during ruxolitinib treatment; the spontaneous disea se regression after therapy interruption might favor early stopping.
| File | Dimensione | Formato | |
|---|---|---|---|
|
kaposi.pdf
Accesso chiuso
Tipologia:
Pdf editoriale (Version of record)
Licenza:
Tutti i diritti riservati
Dimensione
393.4 kB
Formato
Adobe PDF
|
393.4 kB | Adobe PDF | Richiedi una copia |
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
